← Back to headlines
UBS Boosts Bristol-Myers Squibb Price Target Ahead of Milvexian Data
UBS has increased its price target for Bristol-Myers Squibb (BMY) as the market anticipates upcoming data for its drug Milvexian.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
Philippine Official Calls for Probe into Oil Industry Cartel
just now
Philippine President Marcos orders P8-billion aid distribution
just now
Philippines No Longer Southeast Asia's Worst for Fuel Price Hikes, Economic Pain Persists
just now